ATHIX
Price
$26.14
Change
+$0.50 (+1.95%)
Updated
Jun 15 closing price
Net Assets
5.46B
PEMGX
Price
$38.44
Change
+$0.32 (+0.84%)
Updated
Jun 15 closing price
Net Assets
24.11B
Interact to see
Advertisement

ATHIX vs PEMGX

Header iconATHIX vs PEMGX Comparison
Open Charts ATHIX vs PEMGXBanner chart's image
ATHIX vs PEMGX Comparison Chart in %
View a ticker or compare two or three
VS
ATHIX vs. PEMGX commentary
Jun 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATHIX is a Hold and PEMGX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
PEMGX has more cash in the bank: 24.1B vs. ATHIX (5.46B). ATHIX (0.00) and PEMGX (0.00) have matching dividends . ATHIX was incepted earlier than PEMGX: ATHIX (29 years) vs PEMGX (21 years). PEMGX (0.90) is less costly to investors than ATHIX (0.80). ATHIX is a more actively managed with annual turnover of: 62.00 vs. PEMGX (13.70). PEMGX has a lower initial minimum investment than ATHIX: PEMGX (1000) vs ATHIX (5000000). ATHIX annual gain was more profitable for investors over the last year : -11.03 vs. PEMGX (-12.23). PEMGX return over 5 years is better than : -1.85 vs. ATHIX (-14.10).
ATHIXPEMGXATHIX / PEMGX
Total Expense Ratio0.800.9089%
Annual Report Gross Expense Ratio0.800.9089%
Fund Existence29 years21 years-
Gain YTD3.974-6.408-62%
Front LoadN/A6%-
Min. Initial Investment50000001000500,000%
Min. Initial Investment IRAN/AN/A-
Net Assets5.46B24.1B23%
Annual Yield % from dividends0.000.00-
Returns for 1 year-11.03-12.2390%
Returns for 3 years9.4813.4570%
Returns for 5 years-14.10-1.85761%
Returns for 10 years15.8181.5919%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MCHP100.325.08
+5.33%
Microchip Technology
PSNL9.790.20
+2.09%
Personalis
REZI31.62-0.04
-0.13%
Resideo Technologies
NCEL3.20-0.03
-0.93%
NewcelX Ltd.
LENZ6.65-0.12
-1.77%
LENZ Therapeutics